Funded Startups in Cranbury
Seven funded companies are shown for Cranbury, New Jersey, spanning 2022-10-03 (Rocket Pharmaceuticals) through 2026-04-22 (Outlook Therapeutics).
Seven funded companies are shown for Cranbury, New Jersey, spanning 2022-10-03 (Rocket Pharmaceuticals) through 2026-04-22 (Outlook Therapeutics). The largest disclosed round is Rocket Pharmaceuticals’ $100M “Post-IPO Equity” on 2022-10-03, which dwarfs every other disclosed amount in the list (next-highest is IoTecha at $27M on 2024-06-10). Date-wise, there is a clear cluster in 2024: three of the seven rounds fall between 2024-06-10 and 2024-10-02 (IoTecha, Experic, Reteta). Sector concentration also stands out: five of the seven companies are tagged Biotechnology or closely adjacent to it (Outlook Therapeutics, Palatin Technologies, Reteta, Rocket Pharmaceuticals, plus Experic listed as Health Care). Stage labels are dominated by “Series Unknown” entries, appearing in five of the seven rows (Outlook Therapeutics 2026-04-22, Palatin Technologies 2025-11-06, Experic 2024-09-25, IoTecha 2024-06-10, and AffinIT is the exception with “Angel”).
Most recent rounds
7 shownRelated listings
Frequently asked
What’s the largest disclosed round in Cranbury here, and how does it stack up against the others?
Rocket Pharmaceuticals’ $100M Post-IPO Equity (2022-10-03) is the clear outlier; it dwarfs the rest of the disclosed rounds, with the next-highest being IoTecha’s $27M (2024-06-10).
Do the most recent rounds cluster within a tight time window?
Yes. Three rounds were disclosed in roughly four months in 2024—IoTecha $27M (2024-06-10), Experic $10M (2024-09-25), and Reteta $2M (2024-10-02)—before another entry appears later in the list (Palatin Technologies $18M on 2025-11-06, then Outlook Therapeutics $5M on 2026-04-22).
Are Biotechnology-tagged companies over-represented compared with other sectors?
Biotechnology appears in four of the seven entries: Outlook Therapeutics ($5M, 2026-04-22), Palatin Technologies ($18M, 2025-11-06), Reteta ($2M, 2024-10-02), and Rocket Pharmaceuticals ($100M, 2022-10-03). The remaining sectors shown are Health Care (Experic), Financial Services (AffinIT), and Consumer Electronics (IoTecha).
Which stage labels dominate, and what does that imply about comparability across deals?
“Series Unknown” is the most frequent stage classification, showing up in five of the seven rows (Outlook Therapeutics, Palatin Technologies, Experic, IoTecha, and one more is not needed since the count is already five). Only two rows have specific labels—AffinIT is “Angel” with $600K (2025-05-02) and Rocket Pharmaceuticals is “Post-IPO Equity” with $100M (2022-10-03).
Are there outliers on the low end worth flagging alongside the top end?
AffinIT’s $600K Angel round (2025-05-02) is the smallest disclosed amount in the list, contrasting sharply with the $2M-plus range for Reteta ($2M, 2024-10-02) and Experic ($10M, 2024-09-25) and the substantially larger rounds of IoTecha ($27M) and Rocket Pharmaceuticals ($100M).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.